1451 related articles for article (PubMed ID: 29284427)
1. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
[TBL] [Abstract][Full Text] [Related]
2. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease.
Na KS; Mok JW; Kim JY; Rho CR; Joo CK
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5443-50. PubMed ID: 22789923
[TBL] [Abstract][Full Text] [Related]
3. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
4. A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection.
Agrawal R; Balne PK; Veerappan A; Au VB; Lee B; Loo E; Ghosh A; Tong L; Teoh SC; Connolly J; Tan P
Cytokine; 2016 Dec; 88():77-84. PubMed ID: 27585367
[TBL] [Abstract][Full Text] [Related]
5. Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management Study.
Yu K; Bunya V; Maguire M; Asbell P; Ying GS;
Ophthalmology; 2021 Oct; 128(10):1384-1392. PubMed ID: 33785415
[TBL] [Abstract][Full Text] [Related]
6. The Use of Conjunctival Staining to Measure Ocular Surface Inflammation in Patients With Dry Eye.
Yang S; Lee HJ; Kim DY; Shin S; Barabino S; Chung SH
Cornea; 2019 Jun; 38(6):698-705. PubMed ID: 30844839
[TBL] [Abstract][Full Text] [Related]
7. Association of Tear Cytokine Ratios with Symptoms and Signs of Dry Eye Disease: Biomarker Data from the Dry Eye Assessment and Management Study.
Zhao CS; Chen Y; Ying GS; Asbell PA;
Curr Eye Res; 2024 Jan; 49(1):16-24. PubMed ID: 37781912
[TBL] [Abstract][Full Text] [Related]
8. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
[TBL] [Abstract][Full Text] [Related]
9. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?
Essa L; Laughton D; Wolffsohn JS
Cont Lens Anterior Eye; 2018 Feb; 41(1):60-68. PubMed ID: 28811095
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
Messmer EM; von Lindenfels V; Garbe A; Kampik A
Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
[TBL] [Abstract][Full Text] [Related]
11. Tear Interferon-Gamma as a Biomarker for Evaporative Dry Eye Disease.
Jackson DC; Zeng W; Wong CY; Mifsud EJ; Williamson NA; Ang CS; Vingrys AJ; Downie LE
Invest Ophthalmol Vis Sci; 2016 Sep; 57(11):4824-4830. PubMed ID: 27654409
[TBL] [Abstract][Full Text] [Related]
12. Tear Luminex Analysis in Dry Eye Patients.
Zhao H; Li Q; Ye M; Yu J
Med Sci Monit; 2018 Oct; 24():7595-7602. PubMed ID: 30356032
[TBL] [Abstract][Full Text] [Related]
13. Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial.
Pinto-Fraga J; Enríquez-de-Salamanca A; Calonge M; González-García MJ; López-Miguel A; López-de la Rosa A; García-Vázquez C; Calder V; Stern ME; Fernández I
Ocul Surf; 2018 Jul; 16(3):368-376. PubMed ID: 29772277
[TBL] [Abstract][Full Text] [Related]
14. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.
Enríquez-de-Salamanca A; Castellanos E; Stern ME; Fernández I; Carreño E; García-Vázquez C; Herreras JM; Calonge M
Mol Vis; 2010 May; 16():862-73. PubMed ID: 20508732
[TBL] [Abstract][Full Text] [Related]
15. Response profiles to a controlled adverse desiccating environment based on clinical and tear molecule changes.
Fernández I; López-Miguel A; Enríquez-de-Salamanca A; Tesón M; Stern ME; González-García MJ; Calonge M
Ocul Surf; 2019 Jul; 17(3):502-515. PubMed ID: 30936038
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
[TBL] [Abstract][Full Text] [Related]
17. Dry Eye Disease in Patients with Functioning Filtering Blebs after Trabeculectomy.
Ji H; Zhu Y; Zhang Y; Li Z; Ge J; Zhuo Y
PLoS One; 2016; 11(3):e0152696. PubMed ID: 27032098
[TBL] [Abstract][Full Text] [Related]
18. Association of Tear Cytokine Concentrations with Symptoms and Signs of Dry Eye Disease: Baseline Data from the Dry Eye Assessment and Management (DREAM) Study.
Roy NS; Wei Y; Ying GS; Maguire MG; Asbell PA;
Curr Eye Res; 2023 Apr; 48(4):339-347. PubMed ID: 36632643
[TBL] [Abstract][Full Text] [Related]
19. Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease.
Luo G; Xin Y; Qin D; Yan A; Zhou Z; Liu Z
Indian J Ophthalmol; 2018 Jan; 66(1):39-43. PubMed ID: 29283120
[TBL] [Abstract][Full Text] [Related]
20. Effects of corneal nerve density on the response to treatment in dry eye disease.
Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
